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EGFR
mutation
prevalence, %
EGFR
mutation
positive
EGFR
mutation
negative n (N)
Asian/Paciﬁc* 45 1547 1905 31 (3452)
Whitey 24 853 2681 10 (3534)
African Americanz 20 19 78 3 (97)
Asian/Indianx 52 114 106 1 (220)
Data for other populations were absent or too limited for analysis,
including only 3 Latin American (Hispanic) patients.128, 254, 267, 288
*References 7, 17, 32, 35, 48, 49, 55, 133, 184, 185, 191, 257, 264,
269, 270, 272e276, 278, 283e292.
yReferences 17, 32, 191, 192, 253, 273, 288, 292e294.
zReferences 256, 288, 293.
xReference 295.
n, number of studies; N, number of patients.In the article entitled, “PIK3CA Hotspot Mutation Scanning
by a Novel and Highly Sensitive High-Resolution Small
Amplicon Melting Analysis Method” (Volume 12, pages
697e704 of the September 2010 issue of The Journal of
Molecular Diagnostics), in Table 2, in the Selected Group,
there is a typographical error. The Exon 20 mutation
c.3140T>G should be c.3140A>T. The corresponding
amino acid change found in the same table, as well as in the
remainder of the paper, refer to the correct mutation. The
authors apologize for the error.
In the article entitled, “Molecular Testing Guideline for
Selection of Lung Cancer Patients for EGFR and ALK Tyro-
sineKinase Inhibitors:Guideline from theCollege ofAmerican
Pathologists, International Association for the Study of Lung
Cancer, and Association for Molecular Pathology” (Volume
15, pages 415e453 of the July 2013 issue), Table 4 and
Supplemental Table S5 contained errors. These analyses failed
to distinguish between European Spanish and Latin American
(Hispanic) populations. Re-analysis of the four studies origi-
nally cited as providing data for Latin American (Hispanic)
populations led to the re-categorization of 369 patients,
with only 3 remaining Latin American (Hispanic) patients,
a population too limited for meaningful analysis. The recate-
gorization of the remaining 369 patients did not make aCopyright ª 2013 American Society for Investigative Pathology
and the Association for Molecular Pathology.
Published by Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.jmoldx.2013.07.001signiﬁcant change in thedata for theother patient populations as
originally presented in Table 4 and Supplemental Table S5.
The corrected Table 4 appears below, and the corrected
Supplemental Appendix (including Supplemental Table S5)
appears online (see http://dx.doi.org/10.1016/j.jmoldx.2013.
03.001).
